GSK (GSK) Competitors $43.92 +0.15 (+0.34%) Closing price 10/17/2025 03:59 PM EasternExtended Trading$43.60 -0.31 (-0.71%) As of 10/17/2025 07:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock GSK vs. NVS, AZN, NVO, SNY, ARGX, TAK, ONC, INSM, BNTX, and TEVAShould you be buying GSK stock or one of its competitors? The main competitors of GSK include Novartis (NVS), AstraZeneca (AZN), Novo Nordisk A/S (NVO), Sanofi (SNY), argenex (ARGX), Takeda Pharmaceutical (TAK), BeOne Medicines (ONC), Insmed (INSM), BioNTech (BNTX), and Teva Pharmaceutical Industries (TEVA). These companies are all part of the "pharmaceutical products" industry. GSK vs. Its Competitors Novartis AstraZeneca Novo Nordisk A/S Sanofi argenex Takeda Pharmaceutical BeOne Medicines Insmed BioNTech Teva Pharmaceutical Industries GSK (NYSE:GSK) and Novartis (NYSE:NVS) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, profitability, media sentiment, valuation, analyst recommendations, dividends and institutional ownership. Does the media prefer GSK or NVS? In the previous week, Novartis had 20 more articles in the media than GSK. MarketBeat recorded 25 mentions for Novartis and 5 mentions for GSK. Novartis' average media sentiment score of 1.38 beat GSK's score of 0.41 indicating that Novartis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GSK 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Novartis 20 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, GSK or NVS? GSK has a beta of 0.53, suggesting that its stock price is 47% less volatile than the S&P 500. Comparatively, Novartis has a beta of 0.64, suggesting that its stock price is 36% less volatile than the S&P 500. Do insiders & institutionals believe in GSK or NVS? 15.7% of GSK shares are held by institutional investors. Comparatively, 13.1% of Novartis shares are held by institutional investors. 10.0% of GSK shares are held by insiders. Comparatively, 0.0% of Novartis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Is GSK or NVS a better dividend stock? GSK pays an annual dividend of $1.69 per share and has a dividend yield of 3.8%. Novartis pays an annual dividend of $2.59 per share and has a dividend yield of 2.0%. GSK pays out 78.2% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Novartis pays out 37.7% of its earnings in the form of a dividend. Do analysts prefer GSK or NVS? GSK presently has a consensus target price of $37.38, indicating a potential downside of 14.90%. Novartis has a consensus target price of $120.33, indicating a potential downside of 8.46%. Given Novartis' stronger consensus rating and higher probable upside, analysts plainly believe Novartis is more favorable than GSK.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GSK 1 Sell rating(s) 7 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.88Novartis 3 Sell rating(s) 4 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.10 Is GSK or NVS more profitable? Novartis has a net margin of 25.64% compared to GSK's net margin of 10.81%. GSK's return on equity of 49.22% beat Novartis' return on equity.Company Net Margins Return on Equity Return on Assets GSK10.81% 49.22% 11.31% Novartis 25.64%41.08%16.83% Which has better earnings & valuation, GSK or NVS? Novartis has higher revenue and earnings than GSK. Novartis is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGSK$31.63B2.82$3.29B$2.1620.33Novartis$55.19B5.03$11.94B$6.8719.13 SummaryNovartis beats GSK on 14 of the 19 factors compared between the two stocks. Get GSK News Delivered to You Automatically Sign up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GSK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GSK vs. The Competition Export to ExcelMetricGSKMED IndustryMedical SectorNYSE ExchangeMarket Cap$89.26B$3.44B$6.19B$21.83BDividend Yield3.86%2.28%5.70%3.62%P/E Ratio20.3323.0185.5432.43Price / Sales2.82486.53611.7860.31Price / Cash7.8746.9237.1024.21Price / Book5.4410.4112.234.59Net Income$3.29B-$52.77M$3.33B$1.02B7 Day Performance0.90%2.31%1.17%1.31%1 Month Performance8.09%12.59%6.85%-0.93%1 Year Performance13.92%11.18%58.93%9.51% GSK Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GSKGSK1.8515 of 5 stars$43.92+0.3%$37.38-14.9%+14.0%$89.26B$31.63B20.3368,629Dividend CutNVSNovartis2.5323 of 5 stars$129.31-0.6%$120.33-6.9%+12.2%$273.16B$55.19B18.8275,883News CoveragePositive NewsAZNAstraZeneca3.1428 of 5 stars$84.510.0%$86.00+1.8%+8.2%$262.10B$56.50B31.7794,300Trending NewsAnalyst DowngradeShort Interest ↓Analyst RevisionNVONovo Nordisk A/S4.3716 of 5 stars$57.51+1.0%$77.50+34.8%-53.9%$256.76B$311.94B15.8077,349Trending NewsAnalyst ForecastGap DownSNYSanofi4.2075 of 5 stars$48.80+1.5%$62.67+28.4%-7.8%$119.83B$44.46B11.7382,878Upcoming EarningsARGXargenex3.5861 of 5 stars$799.56+0.3%$817.53+2.2%+49.3%$48.93B$3.05B41.001,599Analyst RevisionGap DownTAKTakeda Pharmaceutical3.3802 of 5 stars$13.72+0.0%N/A-2.0%$43.64B$4.48T45.7247,455Analyst ForecastONCBeOne Medicines2.9541 of 5 stars$327.03+2.2%$340.30+4.1%N/A$35.84B$3.81B-189.0311,000INSMInsmed2.9311 of 5 stars$163.94+1.0%$149.06-9.1%+122.4%$34.65B$363.71M-28.711,271News CoveragePositive NewsAnalyst ForecastBNTXBioNTech2.6519 of 5 stars$102.30+0.2%$134.32+31.3%-5.9%$24.59B$2.88B-63.946,772Analyst ForecastTEVATeva Pharmaceutical Industries3.5883 of 5 stars$20.02-0.1%$25.57+27.8%+7.7%$22.96B$16.63B-125.0936,830 Related Companies and Tools Related Companies Novartis Competitors AstraZeneca Competitors Novo Nordisk A/S Competitors Sanofi Competitors argenex Competitors Takeda Pharmaceutical Competitors BeOne Medicines Competitors Insmed Competitors BioNTech Competitors Teva Pharmaceutical Industries Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:GSK) was last updated on 10/19/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GSK PLC Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share GSK With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.